OIG And CMS Agree Medicaid Needs National Drug Price Benchmark Based On Acquisition Cost
This article was originally published in The Pink Sheet Daily
With First DataBank scheduled to end publishing average wholesale price data in September, there is an opportunity for states to switch to pharmacy reimbursement based on actual acquisition costs.
You may also be interested in...
Wholesale drug distributor McKesson settles charges that it reported inflated average wholesale prices (AWPs) for a large number of branded prescription pharmaceuticals, leading to extensive overpayments by the Medicaid program.
State Medicaid agencies may be able to purchase drugs more efficiently by adopting the use of actual acquisition costs as the benchmark for reimbursement, HHS Secretary Kathleen Sebelius suggests in a letter to governors released Feb. 3.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.